AR066012A1 - Derivados oxazolidinona, medicamento, composicion farmaceutica y uso en infecciones bacterianas - Google Patents

Derivados oxazolidinona, medicamento, composicion farmaceutica y uso en infecciones bacterianas

Info

Publication number
AR066012A1
AR066012A1 ARP080101485A ARP080101485A AR066012A1 AR 066012 A1 AR066012 A1 AR 066012A1 AR P080101485 A ARP080101485 A AR P080101485A AR P080101485 A ARP080101485 A AR P080101485A AR 066012 A1 AR066012 A1 AR 066012A1
Authority
AR
Argentina
Prior art keywords
hydrogen
ch2ch2
alkyl
ch2nh
conh
Prior art date
Application number
ARP080101485A
Other languages
English (en)
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of AR066012A1 publication Critical patent/AR066012A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Reivindicacion 1: Un compuesto de formula 1 en la cual R1 es hidrogeno, halogeno, hidroxilo, alcoxilo o ciano; Y1 e Y2 cada uno representa CH y uno o dos de U, V, W y X representa (n) N y los restantes cada uno representa CH o, en el caso de X,puede también representar CRa, y, en el caso de W, puede también representar CRb, o cada uno de U, V, W, X, Y1 e Y2 representa CH o cada uno de U, V, W, X e Y1 representa CH e Y2 representa N, o también uno o, dado que R1 es hidrogeno, dos de U, V,W, X, Y1 e Y2 representa(n) CRc y los restantes cada uno representa CH; Ra representa halogeno; Rb representa alcoxilo, alcoxicarbonilo o alcoxialcoxilo; Rc, cada vez que aparezca, representa de manera independiente hidroxilo o alcoxilo; A esCH2CH(OH), CH2CH(NH2), CH(OH)CHNH2) o CH(NH2)CH2, B es CH2CH2, CH2NH o CONH y D es CH2, o A es CH(OH)CH2 y ya sea B es CH2CH2, CH2NH, N(R2)CO, CONH o N(R2)CH2 y D es CH2 o B es N(R2a)CH2 y D es CH(OH), o A es CH(OH)CH(OH), B es CH2NH o CONH y D esCH2, o A es CH2CH2 y ya sea B es CH2CH2, NR4aCH2, CH2NR3, NHCO, CONR4, CH2O, CH(OH)CH2, CH2CH(OH), CH(NHR3a)CH2, COCH2 o CH2CH2NH y D es CH2 o B es CH2NH y D es CO, o también A es CH2CH2, B es NR4bCH2 o CH2CH2 y D es CH(OH), o A es CH=CH, B esCH2NR5, CONR6 o CH2O y D es CH2, o A es C:::C, B es CH2NH y D es CO, o A es CH2CO, B es NHCH2 y D es CH2, o A es COCH2, B es CH2CH2 o CONH y D es CH2, o A es CH2N(R7) y ya sea B es CH2CH2, COCH2 o CH2CH(OH) y D es CH2 o B es CH2CH2, o CH2CH(OH) y Des CH(OH) o CH(NH2), o A es CONH o CH2O, B es CH2CH2 y D es CH2, o A es NHCH2 y ya sea B es CH2CH2 o CH2NH y D es CH2, o B es CH2NH y D es CO, o A es NHCO, B es CH(R8)NH o CH2CH2 y D es CH2, o A es OCH2, B es CH2, CH2CH2, CH=CH o CONH y D es CH2; R2es hidrogeno o alquilo; R2a es hidrogeno o alquilo; R3 es hidrogeno, fenilalquilo, CO-(CH2)p-COOR3', (CH2)p-COOR3', acilo o aminoalquilo, o también R3 es alquilo que puede estar substituido una o dos veces con grupos hidroxilo, p siendo un enterodesde 1 a 4 y R3' siendo hidrogeno o alquilo; R3a es hidrogeno, acilo o alquilsulfonilo; R4 es hidrogeno o alquilo; R4a es hidrogeno o (CH2)q-COOR4a', o también R4a es alquilo que puede estar substituido una o dos veces con grupos hidroxilo, qsiendo un entero desde 1 a 4 y R4a' siendo hidrogeno o alquilo; R4b es H o alquilo; R5 es hidrogeno o acilo; R6 es hidrogeno, alquilo o fenilalquilo; R7 es hidrogeno o (CH2)r-COOR7', o también R7 es alquilo que puede estar substituido una o dosveces por grupos seleccionados de manera independiente de entre hidroxilo, halogeno, amino y dimetilamino, r siendo un entero desde 1 a 4 y R7' siendo hidrogeno o alquilo; R8 es hidrogeno o alquilo; E es uno de los siguientes grupos de formulas (2);en los cuales Z es CH o N y Q es O o S, o E es un grupo fenilo que está substituido una o dos veces en la(s) posicion(es) meta y/o para por substituyentes cada uno seleccionado de manera independiente desde el grupo que consiste en halogeno, alquiloC1-3, alcoxilo C1-3, trifluorometilo y trifluorometoxilo; o una sal de un tal compuesto.
ARP080101485A 2007-04-11 2008-04-10 Derivados oxazolidinona, medicamento, composicion farmaceutica y uso en infecciones bacterianas AR066012A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2007051292 2007-04-11
IB2008050746 2008-02-29

Publications (1)

Publication Number Publication Date
AR066012A1 true AR066012A1 (es) 2009-07-15

Family

ID=39722506

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080101485A AR066012A1 (es) 2007-04-11 2008-04-10 Derivados oxazolidinona, medicamento, composicion farmaceutica y uso en infecciones bacterianas

Country Status (16)

Country Link
US (1) US8114867B2 (es)
EP (1) EP2146987B1 (es)
JP (1) JP5363457B2 (es)
KR (1) KR101563752B1 (es)
CN (1) CN101657450B (es)
AR (1) AR066012A1 (es)
AU (1) AU2008238894B2 (es)
BR (1) BRPI0809667A2 (es)
CA (1) CA2679069C (es)
CL (1) CL2008001003A1 (es)
ES (1) ES2560870T3 (es)
MX (1) MX2009010641A (es)
PL (1) PL2146987T3 (es)
RU (1) RU2506263C2 (es)
TW (1) TWI415614B (es)
WO (1) WO2008126024A2 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101578234B1 (ko) 2007-12-18 2015-12-16 액테리온 파마슈티칼 리미티드 5-아미노시클릴메틸-옥사졸리딘-2-온 유도체
TW200940551A (en) 2008-02-20 2009-10-01 Actelion Pharmaceuticals Ltd Azatricyclic antibiotic compounds
TWI429643B (zh) 2008-02-22 2014-03-11 Actelion Pharmaceuticals Ltd 唑啶酮衍生物
RU2011108008A (ru) * 2008-08-04 2012-09-10 Актелион Фармасьютиклз Лтд (Ch) Производные трициклического алкиламинометилоксазолидинона
DK2344495T3 (en) 2008-10-07 2015-02-02 Actelion Pharmaceuticals Ltd TRICYCLIC OXAZOLIDINON ANTIBIOTIC COMPOUNDS
ES2395491T3 (es) * 2008-10-10 2013-02-13 Actelion Pharmaceuticals Ltd. 2-Benzotiofenil y 2-naftil-oxazolidinonas y sus análogos azaisósteros como agentes antibacterianos
MX2011005905A (es) 2008-12-12 2011-06-20 Actelion Pharmaceuticals Ltd Derivados de 5-amino-2-(1-hidroxi-etil)-tetrahidropirano.
US20120269830A1 (en) * 2009-12-07 2012-10-25 Lawrence Horowitz Conjugates with improved pharmacokinetic properties
EP2377850A1 (en) 2010-03-30 2011-10-19 Pharmeste S.r.l. TRPV1 vanilloid receptor antagonists with a bicyclic portion
US8952010B2 (en) 2011-02-07 2015-02-10 Daiichi Sankyo Company, Limited Amino group-containing pyrrolidinone derivative
WO2013021363A1 (en) 2011-08-11 2013-02-14 Actelion Pharmaceuticals Ltd Quinazoline-2,4-dione derivatives
CA2854264A1 (en) * 2011-11-08 2013-05-16 Actelion Pharmaceuticals Ltd 2-oxo-oxazolidin-3,5-diyl antibiotic derivatives
EP2785721A1 (en) 2011-11-30 2014-10-08 Actelion Pharmaceuticals Ltd. 3,7-disubstituted octahydro-2h-pyrido[4,3-e][1,3]oxazin-2-one antibiotics
WO2014024056A1 (en) 2012-08-06 2014-02-13 Daiichi Sankyo Company, Limited Pyrrolidine derivatives with antibacterial properties
JP6273278B2 (ja) * 2012-08-17 2018-01-31 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ ベンゾオキサジノンを製造する方法
AU2014255326B2 (en) * 2013-04-16 2018-09-13 Idorsia Pharmaceuticals Ltd Antibacterial biaromatic derivatives
AR102256A1 (es) 2014-10-15 2017-02-15 Actelion Pharmaceuticals Ltd Derivados biaromáticos básicos antibacterianos con sustitución de aminoalcoxi
EP3413976A1 (en) * 2016-02-08 2018-12-19 Redx Pharma PLC Heterocyclic compounds, in particular 2-oxo-4,4,5,5,6,6,7,7-octahydrobenzoxazole derivatives, and their use as antibacterial compounds
EP3414246A1 (en) * 2016-02-08 2018-12-19 Redx Pharma PLC Antibacterial compounds
GB201602235D0 (en) * 2016-02-08 2016-03-23 Redx Pharma Plc Antibacterial compounds
GB2550437B (en) 2016-05-20 2021-06-23 Bugworks Res Inc Heterocyclic compounds useful as anti-bacterial agents and method for production
TW201833120A (zh) 2017-02-17 2018-09-16 瑞士商愛杜西亞製藥有限公司 芳基噁唑啶酮抗生素化合物
US10912780B2 (en) 2017-06-08 2021-02-09 Bugworks Research, Inc. Heterocyclic compounds useful as anti-bacterial agents and method for production thereof
ES2952989T3 (es) * 2017-11-29 2023-11-07 Bugworks Res Inc Compuestos heterocíclicos antibacterianos y su síntesis
PL3774790T3 (pl) * 2018-03-28 2023-07-31 Bugworks Research, Inc. Oksazolidynonowe związki antybiotykowe oraz sposób ich wytwarzania
CN117532894A (zh) * 2023-12-05 2024-02-09 东莞美泰电子有限公司 一种用于保护零件的pu皮革热压贴皮工艺

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU698867B2 (en) 1995-04-21 1998-11-12 Shinnippon Pharmaceutical Inc. Fused imidazo 1,2-a pyridines
ATE207487T1 (de) * 1995-09-01 2001-11-15 Upjohn Co Phenyloxazolidinone mit einer c-c-bindung zu 4-8 gliedrigen heterocyclen
ES2196806T3 (es) 1998-05-08 2003-12-16 Smithkline Beecham Plc Derivados de fenilurea y de feniltiourea.
DE60011570T2 (de) 1999-01-07 2004-11-25 Wyeth Arylpiperazinyl-cyclohexyl indolderivate zur behandlung von depressionen
GB9914486D0 (en) 1999-06-21 1999-08-18 Smithkline Beecham Plc Medicaments
SK18952001A3 (sk) 1999-06-28 2002-11-06 Janssen Pharmaceutica N. V. Inhibítory replikácie respiračného syncyciálneho vírusu
AU2001289749B9 (en) 2000-07-26 2004-08-19 Smithkline Beecham P.L.C. Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity
GB0031086D0 (en) 2000-12-20 2001-01-31 Smithkline Beecham Plc Medicaments
GB0112834D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
GB0112836D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
AU2003224345A1 (en) * 2002-04-30 2003-11-17 Orchid Chemicals & Pharmaceuticals Antibacterial agents
AR040335A1 (es) 2002-06-26 2005-03-30 Glaxo Group Ltd Compuesto de ciclohexano o ciclohexeno, uso del mismo para preparar un medicamento, composicion farmaceutica que lo comprende, procedimiento y compuestos intermediarios de utilidad para preparar dicho compuesto
TW200409637A (en) 2002-06-26 2004-06-16 Glaxo Group Ltd Compounds
ATE463494T1 (de) * 2002-10-10 2010-04-15 Morphochem Ag Komb Chemie Neue verbindungen mit antibakterieller aktivität
US7491714B2 (en) * 2002-12-04 2009-02-17 Glaxo Group Limited Quinolines and nitrogenated derivatives thereof and their use as antibacterial agents
AR042486A1 (es) 2002-12-18 2005-06-22 Glaxo Group Ltd Compuesto de quinolina y naftiridina halosustituido en la posicion 3, procedimiento para preparar el compuesto, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion .
DE10316081A1 (de) * 2003-04-08 2004-10-21 Morphochem AG Aktiengesellschaft für kombinatorische Chemie Neue Verbindungen mit antibakterieller Aktivität
EP1484304A1 (en) 2003-05-28 2004-12-08 Dainippon Ink And Chemicals, Inc. Process for the preparation of fluorophenylalkylene acid derivatives
JP2008502689A (ja) 2004-06-15 2008-01-31 グラクソ　グループ　リミテッド 抗菌剤
FR2872164B1 (fr) * 2004-06-29 2006-11-17 Aventis Pharma Sa Derives de quinoleines-4-substituees, leur procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent
EP1771456A2 (fr) * 2004-07-30 2007-04-11 Palumed SA Molecules hybrides qa ou q est une aminoquinoleine et a est un residu antibiotique, leur synthese et leurs utilisations en tant qu'agent antibacterien
DE102004041163A1 (de) 2004-08-25 2006-03-02 Morphochem Aktiengesellschaft für kombinatorische Chemie Neue Verbindungen mit antibakterieller Aktivität
WO2006032466A2 (en) 2004-09-24 2006-03-30 Actelion Pharmaceuticals Ltd New bicyclic antibiotics
JP5314244B2 (ja) 2004-10-27 2013-10-16 富山化学工業株式会社 新規な含窒素複素環化合物およびその塩
GB0426373D0 (en) 2004-12-01 2005-01-05 Syngenta Ltd Fungicides
ES2351613T3 (es) 2005-03-03 2011-02-08 Santen Pharmaceutical Co., Ltd. Nuevo compuesto cíclico que tiene un grupo quinolilalquiltio.
MX2007012234A (es) 2005-03-31 2008-03-18 Johnson & Johnson Compuestos de pirazol biciclico como agentes antibacterianos.
WO2007016610A2 (en) 2005-08-02 2007-02-08 Glaxo Group Limited Antibacterial agents
WO2007069555A1 (ja) 2005-12-12 2007-06-21 Meiji Seika Kaisha, Ltd. 新規16員環4”-o-カルバモイルアザライド誘導体及びその製造方法
EP1981881B1 (en) 2006-01-26 2011-12-07 Actelion Pharmaceuticals Ltd. Tetrahydropyrane antibiotics

Also Published As

Publication number Publication date
JP2010523645A (ja) 2010-07-15
BRPI0809667A2 (pt) 2014-10-07
KR101563752B1 (ko) 2015-10-27
CN101657450B (zh) 2014-04-23
KR20090130112A (ko) 2009-12-17
CA2679069A1 (en) 2008-10-23
EP2146987A2 (en) 2010-01-27
US8114867B2 (en) 2012-02-14
CA2679069C (en) 2016-06-07
RU2506263C2 (ru) 2014-02-10
CL2008001003A1 (es) 2008-10-17
ES2560870T3 (es) 2016-02-23
WO2008126024A3 (en) 2008-12-04
AU2008238894A1 (en) 2008-10-23
WO2008126024A2 (en) 2008-10-23
CN101657450A (zh) 2010-02-24
TWI415614B (zh) 2013-11-21
PL2146987T3 (pl) 2016-05-31
RU2009141310A (ru) 2011-05-20
TW200843780A (en) 2008-11-16
US20100137290A1 (en) 2010-06-03
MX2009010641A (es) 2009-10-23
EP2146987B1 (en) 2015-12-02
JP5363457B2 (ja) 2013-12-11
AU2008238894B2 (en) 2013-06-20

Similar Documents

Publication Publication Date Title
AR066012A1 (es) Derivados oxazolidinona, medicamento, composicion farmaceutica y uso en infecciones bacterianas
AR070458A1 (es) Derivados de oxazolidina, una composicion farmaceutica que los contiene y su uso en la preparacion de un medicamento para el tratamiento de una infeccion bacteriana.
AR056347A1 (es) Uso de compuestos de pteridina para fabricar medicamentos y composiciones farmaceuticas
ECSP088246A (es) Nuevos derivados de benzotiazolona
AR050261A2 (es) Aminoacidos con afinidad por la proteina alfa-2-delta y composiciones farmaceuticas que los contienen y su uso para preparar un medicamento
AR072471A1 (es) BENZOXACINAS Y BENZOTIACINAS CON ACTIVIDAD INHIBIDORA DE NOS, COMPOSICIoN FARMACÉUTICA QUE LAS COMPRENDE Y SU USO EN EL TRATAMIENTO DEL DOLOR.
AR044078A1 (es) Dihidroquinazolinas sustituidas
ECSP066950A (es) Combinaciones de glicopirrolato y agonistas del adrenoceptor-beta2
DK1163212T3 (da) Amidderivater
AR054129A1 (es) Derivados de 2, 6-quinolinilo, una preparacion farmaceutica que los contiene y su empleo en la fabricacion de medicamentos para el tratamiento de enfermedades dependientes de integrinas alfa4beta1 y/o alfa4beta7
AR053554A1 (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
BRPI0414791A (pt) derivados de purina inibidores da replicação do hiv
AR066095A1 (es) Compuesto de oxadiazol su uso para preparar un medicamento composicion farmaceutica que lo comprende y procedimiento para prepararla
CL2012000999A1 (es) Compuestos derivados de pirazoloespirocetona sustituida, inhibidores de acetil-coa carboxilasa; composicion farmaceutica que los comprende; uso para tratar o retrasar la progresion o el inicio de diabetes tipo 2, higado graso no alcoholico (hgna) o la resistencia hepatica a la insulina.
AR044825A1 (es) Derivados de 5,6-diaril-pirazinas-2-carboxamida y -2-sulfonamidas -3-sustituidas como moduladores de cb1
AR039648A1 (es) Compuestos de aril cetona pirrolo triazina utiles como inhibidores de cinasa y las composiciones farmaceuticas que las contienen
HUP0500173A2 (hu) Alfa-szulfonamido-acetamid-származékok mint béta-amiloid inhibitorok és a vegyületeket tartalmazó gyógyszerkészítmények
ECSP105253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
AR022820A1 (es) Compuestos derivados de piridopiranoacepinas, en forma de isomeros geometricos u opticos puros o de mezcla de tales isomeros, procedimiento para su preparacion, medicamento y composicion farmaceutica.
AR065845A1 (es) Quinolonas y tetrahidroquinolinas y compuestos relacionados con actividad inhibidoria de nos
EA200700901A1 (ru) Производные 2-амидо-4-фенилтиазола, их получение и применение в терапии
UY29234A1 (es) Derivados de adamantano, composiciones farmacéuticas que los contienen, procedimientos de preparación de ambos y aplicaciones.
AR069800A1 (es) Derivados 5- aminociclilmetil - oxazolidin-2- ona
AR074604A1 (es) Derivados de 5-amino-2-(1-hidroxi-etil)-tetrahidropirano.
BRPI0512086A (pt) composto e os sais farmacologicamente aceitáveis do mesmo, composição farmacêutica, e, processo para a preparação de compostos

Legal Events

Date Code Title Description
FB Suspension of granting procedure